Bayer (BAYN) PT Set at €125.00 by Deutsche Bank
Bayer (FRA:BAYN) has been assigned a €125.00 ($148.81) price objective by analysts at Deutsche Bank in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the healthcare company’s stock. Deutsche Bank’s price target would suggest a potential upside of 19.85% from the stock’s current price.
BAYN has been the topic of several other research reports. S&P Global set a €126.00 ($150.00) target price on shares of Bayer and gave the company a “buy” rating in a report on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) target price on shares of Bayer and gave the company a “buy” rating in a report on Wednesday, November 29th. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a report on Monday, December 11th. equinet set a €118.00 ($140.48) target price on shares of Bayer and gave the company a “buy” rating in a report on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($154.76) target price on shares of Bayer and gave the company a “buy” rating in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the stock. Bayer currently has an average rating of “Buy” and a consensus price target of €121.71 ($144.90).
Bayer (FRA:BAYN) opened at €104.30 ($124.17) on Friday. Bayer has a twelve month low of €100.60 ($119.76) and a twelve month high of €123.82 ($147.40). The company has a market cap of $86,150.00 and a price-to-earnings ratio of 27.96.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.